Analytical Data
-
Gene name
IFN-alpha 1/IFNA1
- Application
-
Alternative Names
Interferon alpha-1; IFN-alpha-1; IFNA1
-
Species
Rat
-
Source
HEK293
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P05011
-
Expression Region
C24-S192
-
Protein Length
Full Length of Mature Protein
-
Molecular Weight
20-25 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interferon-alpha 1 (IFN-alpha 1 or IFNA1) is a type I interferon that plays a crucial role in the immune response against viral infections and malignancies. It is produced by various cell types, particularly in response to viral pathogens, and acts by modulating the immune system, enhancing the activities of natural killer cells, and promoting the expression of antigen-presenting molecules. The therapeutic potential of recombinant IFN-alpha 1 has gained significant attention, particularly in the treatment of chronic viral infections such as hepatitis C and certain types of cancers. Its ability to activate immune pathways has led to its use in clinical settings, although its effectiveness can vary among individuals due to genetic and environmental factors. Research has focused on optimizing its therapeutic efficacy, understanding the mechanisms underlying its action, and exploring its use in combinatory therapies. Furthermore, advancements in biotechnology have allowed for the production of recombinant IFNA1 with improved stability and activity, thereby enhancing its clinical applications. As ongoing studies continue to elucidate its diverse biological functions and therapeutic benefits, IFNA1 remains a focal point in the development of novel immunotherapies and antiviral strategies.
